SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX: INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that interim data from a clinical study of an experimental DNA-based prostate cancer vaccine demonstrated that Inovio’s DNA delivery technology significantly enhanced the potency of the gene-based vaccine.
